Salarius Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months EndedJune 30 | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(2,667,358) | $(3,139,723) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,212 | 2,213 |
| Equity-based compensation expense | 56,689 | 162,676 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (11,659) | 403,401 |
| Accounts payable | 337,971 | 16,613 |
| Accrued expenses and other current liabilities | 238,134 | 128,673 |
| Net cash used in operating activities | (2,044,011) | (2,426,147) |
| Financing activities | ||
| Proceeds from issuance of equity securities, net | 626,235 | 88,703 |
| Payments on note payable | (221,866) | (289,643) |
| Net cash provided by (used in) provided by financing activities | 404,369 | (200,940) |
| Net decrease in cash and cash equivalents | (1,639,642) | (2,627,087) |
| Cash and cash equivalents at beginning of period | 2,434,528 | 5,899,910 |
| Cash and cash equivalents at end of period | $794,886 | $3,272,823 |
| Supplemental disclosure of cash flow information: | ||
| Non-cash investing and financing activities: | ||
| Cash paid for interest | $5,800 | $4,816 |
| Accrued issuance costs for issuance of equity securities | 356,984 | 23,585 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.